Insider Transactions in Q2 2021 at Biora Therapeutics, Inc. (BIOR)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2021
|
Jeffrey D. Alter |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+30.18%
|
-
|
|
Jun 14
2021
|
John T. Bigalke Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+38.05%
|
-
|
|
Jun 14
2021
|
Brian L. Kotzin |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+38.05%
|
-
|
|
Jun 14
2021
|
Samuel R Md Nussbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+38.05%
|
-
|
|
Jun 14
2021
|
Lynne Powell |
BUY
Grant, award, or other acquisition
|
Direct |
29,183
+38.05%
|
-
|
|
Jun 14
2021
|
Athyrium Opportunities Fund (A) LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,097,166
+18.2%
|
$16,194,332
$2.47 P/Share
|
|
Jun 14
2021
|
Athyrium Capital Management, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,097,166
+18.2%
|
$16,194,332
$2.47 P/Share
|
|
Jun 01
2021
|
Athyrium Opportunities Fund (A) LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,268,115
+2.18%
|
$2,536,230
$2.86 P/Share
|
|
Jun 01
2021
|
Athyrium Capital Management, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,268,115
+2.18%
|
$2,536,230
$2.86 P/Share
|
|
May 15
2021
|
Matthew T Cooper General Manager, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,400
-1.08%
|
$2,800
$2.36 P/Share
|
|
May 15
2021
|
Hutan Hashemi Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
69
-0.3%
|
$138
$2.36 P/Share
|
|
May 15
2021
|
Clarke Neumann |
SELL
Payment of exercise price or tax liability
|
Direct |
1,505
-1.09%
|
$3,010
$2.36 P/Share
|
|
May 15
2021
|
Troy Seelye Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,925
-2.26%
|
$3,850
$2.36 P/Share
|
|
May 15
2021
|
Sami Shihabi Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
840
-0.66%
|
$1,680
$2.36 P/Share
|
|
Apr 15
2021
|
Harry Stylli Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
229,885
+1.53%
|
-
|
|
Apr 15
2021
|
Matthew T Cooper General Manager, Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
80,460
+38.26%
|
-
|
|
Apr 15
2021
|
Eric D Esparbes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,690
-6.34%
|
$41,070
$3.41 P/Share
|
|
Apr 15
2021
|
Eric D Esparbes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
123,382
+36.38%
|
-
|
|
Apr 15
2021
|
Hutan Hashemi Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,494
+50.0%
|
-
|
|
Apr 15
2021
|
Clarke Neumann |
BUY
Grant, award, or other acquisition
|
Direct |
87,356
+38.75%
|
-
|
|
Apr 15
2021
|
Troy Seelye Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,231
-6.8%
|
$18,693
$3.41 P/Share
|
|
Apr 15
2021
|
Troy Seelye Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,836
+37.45%
|
-
|
|
Apr 15
2021
|
Sami Shihabi Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
91,954
+41.99%
|
-
|
|
Apr 15
2021
|
Damon Silvestry Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,681
-1.25%
|
$11,043
$3.41 P/Share
|
|
Apr 15
2021
|
Damon Silvestry Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,107
+19.9%
|
-
|